Active Stocks in Review: LinkedIn (NYSE:LNKD), PDL BioPharma (NASDAQ:PDLI)

NEW YORK, NY - JANUARY 25:  Chief Executive Officer David Lissy, joined by members of Bright Horizons’ leadership team celebrate their IPO at the New York Stock Exchange on January 25, 2013 in New York City. (Photo by Ben Hider/NYSE Euronext)NEW YORK, NY - JANUARY 25: Chief Executive Officer David Lissy, joined by members of Bright Horizons’ leadership team celebrate their IPO at the New York Stock Exchange on January 25, 2013 in New York City. (Photo by Ben Hider/NYSE Euronext)

On Tuesday, September 9th, 2015: Shares of LinkedIn Corp (NYSE:LNKD) followed a gain of 0.02% while closing down to $183.22.


LinkedIn Corporation is truly a mind-blowing company that has overtaken everything by storm. The company together with its auxiliaries, operates an online professional network worldwide. The company, through its proprietary platform, allows members to create, manage, and share their professional identity online; build and engage with their professional net operates; access shared knowledge and insights; and find business opportunities.

LinkedIn Corporation (LNKD), is proud to be the world’s largest professional network on the Internet, declared recently the launch of a new quarterly series, LinkedIn Lists, which celebrates different types of members and companies that are doing extraordinary work and transforming their fields.

The first list in the series focuses on the LinkedIn Next Wave, which spotlights the top 150 professionals across 15 industries — all 35 and under. Like all of LinkedIn’s content efforts, the Next Wave derived from a partnership between editors and algorithms: How can the data assist find the leaders you may not know about — but should. We also asked LinkedIn Influencers, ~500 top minds in business who write and share on LinkedIn, for their recommendations.

Shares of PDL BioPharma Inc (NASDAQ:PDLI) observed a gain of 1.74% while closing down to final price of $5.27.

PDL BioPharma, Inc. is popular brand name that manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.

PDL BioPharma, Inc. (PDLI) confirmed that it has reached a credit agreement with CareView Communications, Inc. (CRVW) whereby PDL will provide CareView with up to $40 million of secured debt financing. CareView is an information technology provider to the healthcare industry focused on patient care monitoring.

Under the credit agreement, PDL will provide CareView with up to $40 million of debt financing in two tranches of $20 million, based upon the achievement of specified milestones. Each tranche has a five year maturity.  PDL will receive interest on the principal amount outstanding and has a security interest in substantially all of CareView’s assets.  As part of the transaction, PDL received a warrant to purchase about 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share.

Notes to the Stakeholders:

This article is the intellectual property of The purpose of penning down this article has been just to share information. Moreover, it is firmly believed that all the information that are revealed in this article are believed to be from reliable sources, however, we do not make any representations or warranties whatsoever of any kind, express or implied, as far as the completeness, accurateness, or reliability with respect to this article is concerned.

All the respectable visitors to this website are kindly advised to conduct their own independent research into individual stocks prior to making a purchase decision.

This article contains an advanced information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as statements regarding the forseeable frequent growth of the market for the corporation’s products, the corporation’s capability to fund its capital requirement in the close-to term and in the long term; pricing pressures; etc.

Furthermore, any statement that expresses or involves discussions with respect to forecast, expectations, beliefs, strategy, projection, objectives, aims, assumption, or future events or performance may be forward looking statements. In addition, the forward-looking statements are wholly and solely based upon expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. An easy way to identify the forward looking statements is through the use of such words as be expecting, will, foresee, guess, considered, or by statements that indicates certain actions may, could, should/might occur.


About the Author

Vince Hart
Vince Hart is a quant reporter at JBH News. He studied mathematics at the University of Chicago and Purdue University. :)